

Sandra K Kostyk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4010157/publications.pdf>

Version: 2024-02-01

47
papers

3,029
citations

236612

25
h-index

243296

44
g-index

47
all docs

47
docs citations

47
times ranked

3512
citing authors

#	ARTICLE	IF	CITATIONS
1	AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. <i>Lancet Neurology</i> , The, 2011, 10, 309-319.	4.9	582
2	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 543.	4.5	312
3	Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. <i>JAMA Neurology</i> , 2017, 74, 977.	4.5	209
4	Visual orienting deficits in frogs with various unilateral lesions. <i>Behavioural Brain Research</i> , 1982, 6, 379-388.	1.2	180
5	Reliability and Validity of the Tinetti Mobility Test for Individuals With Parkinson Disease. <i>Physical Therapy</i> , 2007, 87, 1369-1378.	1.1	172
6	Referred phantom sensations and cortical reorganization after spinal cord injury in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 14703-14708.	3.3	122
7	Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 39-47.	4.9	112
8	A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. <i>Movement Disorders</i> , 2013, 28, 1407-1415.	2.2	111
9	A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. <i>Neurology</i> , 2017, 88, 152-159.	1.5	104
10	Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease. <i>JCI Insight</i> , 2017, 2, e90133.	2.3	74
11	Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease. <i>Archives of Neurology</i> , 2008, 65, 1582-9.	4.9	71
12	Neuronal organization underlying visually elicited prey orienting in the frog ^I . Effects of various unilateral lesions. <i>Neuroscience</i> , 1987, 21, 41-55.	1.1	70
13	Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease. <i>Gait and Posture</i> , 2016, 50, 1-7.	0.6	69
14	Video game play (Dance Dance Revolution) as a potential exercise therapy in Huntington's disease: a controlled clinical trial. <i>Clinical Rehabilitation</i> , 2013, 27, 972-982.	1.0	65
15	Neuronal organization underlying visually elicited prey orienting in the frog ^{II} . Anatomical studies on the laterality of central projections. <i>Neuroscience</i> , 1987, 21, 57-82.	1.1	64
16	Progranulin expression is upregulated after spinal contusion in mice. <i>Acta Neuropathologica</i> , 2010, 119, 123-133.	3.9	63
17	Substance P immunoreactive astrocytes are present in multiple sclerosis plaques. <i>Brain Research</i> , 1989, 504, 284-288.	1.1	55
18	Neuronal organization underlying visually elicited prey orienting in the frog ^{III} . Evidence for the existence of an uncrossed descending tectofugal pathway. <i>Neuroscience</i> , 1987, 21, 83-96.	1.1	54

#	ARTICLE	IF	CITATIONS
19	Fall risk assessment using the Tinetti mobility test in individuals with Huntington's disease. <i>Movement Disorders</i> , 2010, 25, 2838-2844.	2.2	54
20	Assistive devices alter gait patterns in Parkinson disease: Advantages of the four-wheeled walker. <i>Gait and Posture</i> , 2013, 38, 20-24.	0.6	43
21	The potential binocular field and its tectal representation in rana pipiens. <i>Journal of Comparative Neurology</i> , 1980, 190, 175-185.	0.9	40
22	The Impact of Different Types of Assistive Devices on Gait Measures and Safety in Huntington's Disease. <i>PLoS ONE</i> , 2012, 7, e30903.	1.1	40
23	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS). <i>JAMA Neurology</i> , 2016, 73, 102.	4.5	38
24	Clinimetric properties of the Tinetti Mobility Test, Four Square Step Test, Activities-specific Balance Confidence Scale, and spatiotemporal gait measures in individuals with Huntington's disease. <i>Gait and Posture</i> , 2014, 40, 647-651.	0.6	28
25	Frog Prey Capture Behavior: Between Sensory Maps and Directed Motor Output. , 1983, , 331-347.		27
26	Regulation of neural cell survival and differentiation by peptide growth factors. <i>Current Opinion in Cell Biology</i> , 1990, 2, 1050-1057.	2.6	26
27	The Effects of Collagen-Based Implants on Early Healing of the Adult Rat Spinal Cord. <i>Tissue Engineering</i> , 1997, 3, 309-317.	4.9	26
28	Paired Studies Comparing Clinical Profiles of Lewy Body Dementia with Alzheimer's and Parkinson's Diseases. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 995-1004.	1.2	23
29	Robust axonal growth and a blunted macrophage response are associated with impaired functional recovery after spinal cord injury in the MRL/MpJ mouse. <i>Neuroscience</i> , 2008, 156, 498-514.	1.1	20
30	Prey orienting in frogs: Accounting for variations in output with stimulus distance. <i>Journal of Comparative Physiology A: Neuroethology, Sensory, Neural, and Behavioral Physiology</i> , 1985, 156, 775-785.	0.7	19
31	Cognitive Dysfunction Contributes to Mobility Impairments in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2017, 6, 363-370.	0.9	19
32	Quantitative biomechanical assessment of trunk control in Huntington's disease reveals more impairment in static than dynamic tasks. <i>Journal of the Neurological Sciences</i> , 2017, 376, 29-34.	0.3	18
33	Dopaminergic Modulation of Semantic Priming in Parkinson Disease. <i>Cognitive and Behavioral Neurology</i> , 2008, 21, 134-137.	0.5	17
34	Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1210-1218.	0.9	16
35	Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients: A Randomized Phase 2 Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3682.	1.0	15
36	Ovulation in Immature Rats in Relation to the Time and Dose of Injected Human Chorionic Gonadotropin or Pregnant Mare Serum Gonadotropin. <i>Biology of Reproduction</i> , 1978, 19, 1102-1107.	1.2	12

#	ARTICLE	IF	CITATIONS
37	Unusual expression of the HU paraneoplastic antigen in the visual system. NeuroReport, 1996, 7, 1549-1552.	0.6	12
38	Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease. Journal of the Neurological Sciences, 2014, 347, 219-223.	0.3	11
39	Age of onset and behavioral manifestations in Huntington's disease: An <scp>Enrollâ€HD</scp> cohort analysis. Clinical Genetics, 2021, 99, 133-142.	1.0	9
40	Symptomatic gallstones in patients with spinal cord injury. Journal of Gastrointestinal Surgery, 2000, 4, 642-647.	0.9	7
41	Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease. Neurology: Genetics, 2020, 6, e430.	0.9	6
42	Orienting behavior of juvenile frogs with both a pre-metamorphically rotated and a normal eye. Behavioural Brain Research, 1982, 4, 55-62.	1.2	4
43	The Step Test Evaluation of Performance on Stairs (STEPS): Validation and reliability in a neurological disorder. PLoS ONE, 2019, 14, e0213698.	1.1	4
44	Immediate effects of treadmill walking in individuals with Lewy body dementia and Huntingtonâ€™s disease. Gait and Posture, 2021, 86, 186-191.	0.6	4
45	Pond neurons. Neurology, 2018, 90, 90-90.	1.5	1
46	F41â€...The proof-hd phase 3 study: pridopidineâ€™s outcome on function in huntington disease (PROOF). , 2021, , .		1
47	Carpet Neurons and the Bottom Line. Neurology, 2021, 97, 641-641.	1.5	0